Trends and changes in the clinical use of lamotrigine

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 2, 2009, Pages 132-139

  Reimers, Arne ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Lamotrigine; Pattern of use; Pharmaco epidemiology; Trends

Indexed keywords

ACETYLSALICYLIC ACID; ALIMEMAZINE; CARBAMAZEPINE; CHLORPROTHIXENE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DIAZEPAM; ESCITALOPRAM; ETHINYLESTRADIOL; ETIRACETAM; FLUOXETINE; LAMOTRIGINE; LITHIUM; MIANSERIN; MIRTAZAPINE; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; OXAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; QUETIAPINE; RISPERIDONE; SERTRALINE; THYROXINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INTOXICATION; DRUG MONITORING; DRUG OVERDOSE; DRUG UTILIZATION; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; REFERENCE VALUE; SCHOOL CHILD; SEX DIFFERENCE; BLOOD; DRUG USE; FACTUAL DATABASE; INFANT; MENTAL DISEASE; MIDDLE AGED; NEUROLOGIC DISEASE; NORWAY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MENTAL DISORDERS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NORWAY; RETROSPECTIVE STUDIES; TRIAZINES; YOUNG ADULT;

EID: 62649120573     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1690     Document Type: Article

References (23)

1. May TW, Rambeck B, Jürgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996; 18: 523-531.
2. Beyer JL, Burchitt B, Gersing K, Krishnan KR. Patterns of pharmacotherapy and treatment response in elderly adults with bipolar disorder. Psychopharmacol Bull 2008; 41: 102-114.
3. Knoester PD, Belitser SV, Deckers CL, et al. Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in The Netherlands. J Clin Pharm Ther 2004; 29: 131-138.
4. Wong IC, Mawer GE, Sander JW, et al. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia 2001; 42: 1354-1358.
5. Wong IC, Mawer GE, Sander JW. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001; 42: 237-244.
6. Knoester PD, Keyser A, Renier WO, et al. Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study. Epilepsy Res 2005; 65: 93-100.
7. Knoester PD, Belitser SV, Deckers CL, et al. Diffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice. Eur J Clin Pharmacol 2004; 60: 751-758.
8. May TW, Rambeck B, Airgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996; 18: 523-531.
9. Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J. Clin Psychopharmacol 2005; 25: 342-348.
10. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-627.
11. Wilbur K, Ensom MH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 2000; 38: 355-365.
12. Tennis P, Eldridge RR. International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43: 1161-1167.
13. Morrell MJ. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003; 44 (Suppi 4): 11-20.
14. Reimers A, Skogvoll E, Sund JK, et al. Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions. Eur J Clin Pharmacol 2007; 63: 687-692.
15. Reimers A, Skogvoll E, Sund JK, et al. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 2005; 25: 342-348.
16. WHO ATC/DDD Index 2008. http://www.whocc.no/atcddd/indexdata-base/ index.php?query=N03AX09 (accessed 9 April 2008).
17. Koristkova B, Sjoqvist F, Grundmann M, et al. The use of TDM data to assess the validity of defined daily doses of antiepileptics: a comparison between a Czech and Swedish University Hospital. Ther Drug Monit 2006; 28: 589-593.
18. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-443.
19. Morris RG, Black AB, Harris AL, et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998; 46: 547-551.
20. Froscher W, Keller F, Vogt H, Kramer G. Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels. Epileptic Disord 2002; 4: 49-56.
21. Hirsch LJ, Weintraub D, Du Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63: 1022-1026.
22. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-363.
23. Morris RG, Lee MY, Cleanthous X, et al. Long-term follow-up using a higher target range for lamotrigine monitoring. Ther Drug Monit 2004; 26: 626-632.